GRCE earnings date and last-quarter result: last quarter beat, P/E -4.26. Updated 2026-07-23.
Grace Therapeutics (GRCE) Research Hub
Grace Therapeutics (GRCE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.81 USD (-6.22%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.26, market cap 0.04B. This hub links to the full technical, earnings and options research available for GRCE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.81 USD (-6.22%) |
| 52-week range | 1.67 USD – 2.58 USD |
| Trend regime | Range |
| 14-day RSI | 32.4 (Bearish) |
| Trailing P/E | -4.26 |
| Market cap | 0.04B |
| Dividend yield | 0.00% |
Available research for GRCE
Covered Call on GRCE: how it works, illustrative setup around the real 1.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GRCE: how it works, illustrative setup around the real 1.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GRCE: how it works, illustrative setup around the real 1.81 USD price, max profit/loss, breakeven and when to use it. Educational.
GRCE technical analysis: range, last 1.81 USD, RSI 32.4, 52w range 1.67 USD–2.58 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GRCE in?
Grace Therapeutics (GRCE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GRCE in an uptrend or downtrend?
As of 2026-10-26, GRCE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GRCE's trailing P/E ratio?
GRCE's trailing P/E is -4.26, with a market cap of 0.04B. See the earnings research page for full valuation detail.